PARP Inhibitors Market Prevalent Opportunities upto 2026 With Drug – Olaparib, Niraparib, Rucaparib, and Talazoparib
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP Inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP Inhibitors used to treat subset of ovarian cancer. Currently only PARP Inhibitors approved in the market is Lynparza from AstraZeneca and several PARP Inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP Inhibitors mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.
PARP Inhibitors Market: Drivers and Restraints
PARP Inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP Inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.
To Get the Sample Copy of Report visit @https://www.futuremarketinsights.com/reports/sample/rep-gb-3197
PARP Inhibitors market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP Inhibitors over the forecast period. In addition, development of PARP Inhibitors have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP Inhibitors over the forecast period.
PARP Inhibitors Market: Segmentation
PARP Inhibitors market has been segmented on the basis of drug type, indication, distribution channel and Region.
Based on the drug type, the PARP Inhibitors market is segmented into the following:
Based on the indication, the PARP Inhibitors market is segmented into the following:
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
Based on the distribution channel, the PARP Inhibitors market is segmented into the following:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
PARP Inhibitors Market: Overview
PARP Inhibitors market is witnessing significant changes due to increasing opportunity owing to rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis who’s pipeline PARP Inhibitors shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP Inhibitors. PARP Inhibitors market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.
Ask an Analyst @https://www.futuremarketinsights.com/ask-question/rep-gb-3197
PARP Inhibitors Market: Region-wise Outlook
Geographically, PARP Inhibitors market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP Inhibitors market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP Inhibitors market by the regions over the forecast period. Asia Pacific PARP Inhibitors market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region.
PARP Inhibitors Market: Key Players
Some of the players in the global PARP Inhibitors market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil and Rest of Latin America)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg and Rest of Western Europe)
- Eastern Europe (Poland, Russia and Rest of Eastern Europe)
- Asia Pacific (China, India, ASEAN, Australia & New Zealand)
- Middle East and Africa (GCC, S. Africa, and Rest of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Buy this report @https://www.futuremarketinsights.com/checkout/3197
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Table Of Content
- Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
- Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
- Key Market Trends
3.1. Key Trends Impacting The Market
- Key Inclusions
4.1. Key Regulations
4.2. Pipeline Analysis
4.3. Epidemiology for Different Cancer, By Country
- Global PARP Inhibitors Market Demand (in Value or Size in US$ Mn) Analysis 2015-2018 and Forecast, 2019-2026
5.1. Historical Market Value (US$ Mn) Analysis, 2015-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2026
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org